- Home
- SIGA vs VOR Comparison
SIGA vs VOR Comparison
Compare SIGA & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SIGA | VOR |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 486.2M | 562.6M |
| IPO Year | 2016 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SIGA | VOR |
|---|---|---|
| Price | $6.34 | $15.19 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $64.78 |
| AVG Volume (30 Days) | 336.9K | ★ 696.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 9.65% | N/A |
| EPS Growth | N/A | ★ 2.86 |
| EPS | ★ 0.40 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $132.36 | N/A |
| P/E Ratio | $15.61 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.95 | $0.13 |
| 52 Week High | $9.62 | $49.95 |
Technical Indicators
Market Signals| Indicator | SIGA | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 41.48 | 54.78 |
| Support Level | $6.10 | $11.76 |
| Resistance Level | $6.58 | $16.95 |
| Average True Range (ATR) | 0.22 | 1.13 |
| MACD | -0.05 | 0.16 |
| Stochastic Oscillator | 23.26 | 55.23 |
Price Performance
Historical ComparisonAbout SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.